Genenta Science S.p.A.
Genenta Science S.p.A. is an Italy-based company with operations historically centered on biotechnology and cell therapy, and later expanded into owning and building industrial businesses through a holding-company structure. Its portfolio now spans aerospace, defense, national security, and biotechnology/biosecurity, with assets and subsidiaries concentrated in Italy and a listed presence in the United States.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2022–2025
Liiketoiminta
Osuus liikevaihdostaCell-therapy research assets, intellectual property, and partnered development activities.
Majority or strategic equity stakes in privately held operating businesses.
Precision components, systems, and manufacturing for aerospace and defense customers.
Cybersecurity, AI-driven intelligence, quantum, and secure communications themes.
Tactical rifles, chassis systems, mounts, bipods, and related accessories.
Asiakkaat
Genenta’s customer base is best understood through the operating businesses it owns or consolidates: defense and aerospace buyers, national-security and critical-infrastructure end users, and industrial or government-linked customers in regulated sectors. Its biotechnology assets are more partnership-driven and rely on collaborators, external capital, or strategic partners rather than broad commercial sales. The company’s portfolio approach means customer exposure is tied to end-markets served by its subsidiaries rather than to a single product line.
Buy precision mechanical components and engineered systems for space and defense programs.
Buy tactical rifles, chassis systems, optics mounts, bipods, and related accessories.
Buy national-security-related capabilities such as secure communications or critical infrastructure solutions.
Collaborate on cell-therapy and biosecurity programs to share development risk and funding.
Acquire or partner with established Italian businesses seeking long-term ownership stability.
Strategia
The company is repositioning itself as a long-term consolidator of privately held Italian businesses in strategic sectors, with an emphasis on control ownership and operational integration. It is also keeping its biotechnology platform alive in a partnership-led format, which reduces the need for large internal R&D spending unless backed by external capital. The strategy aims to combine a Nasdaq-listed structure with regulated-sector industrial assets that can be bought, improved, and held over the long term.
Control ownership allows the company to influence operations and capture long-term value.
National-security-regulated sectors can create strategic barriers and recurring demand.
Partnerships limit capital intensity while keeping the cell-therapy platform alive.
A simpler structure should improve focus and resource allocation.
Maantiede
Genenta is headquartered in Milan, Italy, and its strategic focus is centered on acquiring and building businesses in Italy and Europe. It also maintains a U.S. public-company structure, but the recent disclosures indicate the company is winding down direct U.S. operating activity and concentrating capital and management attention on European assets. Geography matters because the portfolio is tied to Italian national-security-regulated sectors and to European industrial and defense demand.
Riskit
The company faces execution risk as it shifts from a biotech identity to a multi-asset industrial consolidator, because acquisitions require integration, governance, and capital discipline. Its portfolio also depends on regulated sectors and government-sensitive industries, which can be affected by approvals, security restrictions, and changes in procurement or policy. Biotechnology remains a long-duration risk area because partnered development can still fail scientifically, commercially, or financially.
- Acquisition integration riskVaikutus: KorkeaTodennäköisyys: Korkea
The company is building value through purchases of operating businesses and must integrate governance and operations.
Kohdistuu - Regulatory and approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Target sectors are subject to Italy's Golden Power and other national-security controls.
Kohdistuu: Italian strategic-sector acquisitions
- Biotechnology development riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Cell-therapy and biosecurity assets depend on scientific progress and partner support.
Kohdistuu: Retained biotechnology platform
- Geographic concentration riskVaikutus: KeskitasoTodennäköisyys: Korkea
The strategic focus is centered on Italy and Europe, limiting diversification.
Kohdistuu: Italian industrial portfolio
Kirjanpito
Harkinnanvaraiset erätAcquisitions require fair-value allocation of assets and liabilities, affecting future depreciation, amortization, and impairment.
Vaikutus: Can materially change reported earnings after each acquisition
Minority stakes such as the Sòphia HT investment require judgment on carrying value and share of results.
Vaikutus: Affects reported net income and balance sheet value
Retained biotech assets and acquired intangibles depend on assumptions about future cash flows and partner support.
Vaikutus: Potential non-cash write-downs
Management presents EBITDA as a supplemental measure, so investors must reconcile it to IFRS results.
Vaikutus: Can affect comparability across periods
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Centessa Pharmaceuticals plc
Pharmaceutical Preparations
Centessa Pharmaceuticals plc is a clinical-stage biopharmaceutical company built around an asset-centric model, where each program is developed with its own…
Azenta, Inc.
AZTA · Special Industry Machinery, NEC
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
Septerna, Inc.
SEPN · Pharmaceutical Preparations
Septerna is a U.S.-based biotechnology company focused on discovering and developing small-molecule medicines for diseases driven by G protein-coupled receptors (GPCRs).
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Cytta Corp.
Services-Prepackaged Software
Päivitetty: 28.9.2026